Skip to content
PICO Portalanswers from OpenAlex

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

PaperCitations, authors & open-access status

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is a paper indexed in PICO Portal from OpenAlex.

How many citations does Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes have?

PICO Portalcitation count

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has 67 citations in the OpenAlex counts PICO Portal stores.

When was Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes published?

PICO Portalyear

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has 2020 year in the PICO Portal index.

What is the open-access status of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?

PICO Portaloa status

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has hybrid oa status in the PICO Portal index.

What is the DOI of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?

PICO Portaldoi

The DOI for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.

What is the PMID of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?

PICO Portalpmid

The PMID for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.

What is the OpenAlex record for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?

PICO Portalopenalex

The OpenAlex for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial